Candriam S.C.A. Chinook Therapeutics, Inc. Transaction History

Candriam S.C.A.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 08, 2023	SELL	$18.66 - $38.58 $1.87 Million - $3.86 Million	-100,000 Reduced 10.8%	826,155 $31.7 Million
Q4 2022 Feb 13, 2023	BUY	$18.63 - $27.35 $1.02 Million - $1.5 Million	55,000 Added 6.31%	926,155 $24.3 Million
Q2 2022 Aug 03, 2022	SELL	$12.59 - $18.8 $3.96 Million - $5.91 Million	-314,159 Reduced 26.5%	871,155 $15.2 Million
Q1 2022 May 13, 2022	BUY	$12.02 - $16.69 $966,552 - $1.34 Million	80,412 Added 7.28%	1,185,314 $19.4 Million
Q4 2021 Feb 10, 2022	BUY	$10.69 - $16.83 $2.16 Million - $3.41 Million	202,365 Added 22.42%	1,104,902 $18 Million
Q3 2021 Nov 09, 2021	BUY	$11.5 - $14.86 $315,249 - $407,357	27,413 Added 3.13%	902,537 $11.5 Million
Q2 2021 Jul 20, 2021	BUY	$13.6 - $18.98 $11.9 Million - $16.6 Million	875,124 New	875,124 $12.4 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.